Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2010-08-31
2011-12-06
Spivack, Phyllis G. (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
08071647
ABSTRACT:
Method for suppressing adhesion of the intestines or therapeutic treatment of adhesion of the intestines comprising administering to a patient in need thereof a therapeutically effective amount of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid. There is also provided a medicament for suppressing adhesion of the intestines and/or therapeutic treatment of bowel diseases such as inflammatory bowel diseases, including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
REFERENCES:
patent: 4703110 (1987-10-01), Shudo
patent: 5776915 (1998-07-01), Peterson et al.
patent: 5929069 (1999-07-01), Shudo
patent: 6589989 (2003-07-01), Bollag et al.
patent: 2005/0234130 (2005-10-01), Nagai et al.
patent: 2008/0021108 (2008-01-01), Shudo et al.
patent: 2008/0139842 (2008-06-01), Shudo et al.
patent: 2008/0182905 (2008-07-01), Takenaga et al.
patent: 2008/0207768 (2008-08-01), Shudo et al.
patent: 2008/0255069 (2008-10-01), Shudo et al.
patent: 2009/0253796 (2009-10-01), Nagai et al.
patent: 2010/0004203 (2010-01-01), Shudo et al.
patent: 1500401 (2005-01-01), None
patent: 61-22047 (1986-01-01), None
patent: 61-76440 (1986-04-01), None
patent: 7-101857 (1995-04-01), None
patent: 10-59951 (1998-03-01), None
patent: 99/09969 (1999-03-01), None
patent: 03/89005 (2003-10-01), None
patent: 2005/087129 (2005-09-01), None
patent: 2007/007198 (2007-01-01), None
Ellis, H., European Journal of Surgery (Suppl.), (1997), (577), pp. 5-9 (Abstract).
Extended European Search Report issued in connection with the counterpart European application, on Jun. 17, 2010.
Morzsik et al., “Retiniods as Scavengers and Gastric Cytoprotection in Animals, Human Beings and Patients with Peptic Ulcer”, Oxygen Free Radicals and Scavengers in the Natural Sciences, Jan. 1, 1993, pp. 329-338.
Sako et al, “4-[3, 5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression”, In Vivo, vol. 19, No. 1, Jan. 2005, pp. 125-132.
Desreumaux et al. “Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma γ (PPARγ) heterodimer: A basis for new therapeutic strategies”, Journal of Experimental Medicine, vol. 193, No. 7, Apr. 2, 2001, pp. 827-838.
Kagechika et al. “Retinobenzoic Acids. 1. Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity”J Med. Chem.vol. 31, No. 11, pp. 2182-2192, 1988.
Evans, R.M. “The Steroid and Thyroid Hormone Receptor Superfamily”Sciencevol. 240, pp. 889-895, 1988.
Petkovich et al. “A Human Retinoic Acid Receptor Which Belongs to the Family of Nuclear Receptors”Naturevol. 330, pp. 444-450, 1987.
Mangelsdorf et al. “Nuclear Receptor that Identifies a Novel Retinoic Acid Response Pathway”Naturevol. 345, pp. 224-229, 1990.
Hashimoto, Y. “Retinobenzoic Acids and Nuclear Retinoic Acid Receptors”Cell Structure and Functionvol. 16, No. 2, pp. 113-123, 1991.
Hashimoto et al. “Expression of Retinoic Acid Receptor Genes and the Ligand-Binding Selectivity of Retinoic Acid Receptors (RAR's)”Biochem. Biophys. Res. Commun.vol. 166, No. 3, pp. 1300-1307, 1990.
Wright et al. “Vitamin A Therapy in Patients with Crohn's Disease”Gastroenterologyvol. 88, No. 2, pp. 512-514, 1985.
Selenkow, H.A. “Remission of Hyperthyroidism and Oral Contraceptive Therapy”The Journal of the American Medical Association(JAMA) vol. 252, No. 17, p. 2463, 1984.
Gold et al. “The Retinoids and Inflammatory Bowel Disease”Arch. Dermatol.vol. 124, No. 3, pp. 325-326, 1988.
Godfrey et al. “Treatment of Severe Acne with Isotretinoin in Patients with Inflammatory Bowel Disease”Br. J. Dermatol.vol. 123, No. 5, pp. 653-655, 1990.
Harewood et al. “Treatment of Acute Myeloid Leukemia M3 in a Patient with Chrone's Disease”Cancer Invest.vol. 18, No. 1, p. 98, 2000.
De Thé et al. “Retinoids: 10 Years on.” Ed. J.H. Saurat, Basel Karger, pp. 2-9, 1991.
Yamakawa et al. “Retinobenzoic Acids. 5. Reinoidal Activities of Compounds Having a Trimethylsilyl or Trimethylgermyl Group(s) in Human Promyelocytic Leukemia Cells HL-60”J. Med. Chem.vol. 33, No. 5, pp. 1430-1437, 1990.
Wallace et al. “An Orally Active Inhibitor of Leukotriene Synthesis Accelerates Healing in a Rat Model of Colitis”Am. J Physiol.vol. 258, pp. G527-G534, 1990.
Rohrmann et al. “Association Between Serum Concentrations of Micronutrients and Lower Urinary Tract Symptoms in Older Men in the Third National Health and Nutrition Examination Survey”Urologyvol. 64, No. 3, pp. 504-509, 2004.
Basu et al. “Vitamin A Homeostasis and Diabetes Mellitus”Nutritionvol. 13, No. 9, pp. 804-806, 1997.
Tuitoek et al. “Streptozotocin-Induced Diabetes in Rats is Associated with Impaired Metabolic Availability of Vitamin A (Retinol)”British Journal of Nutritionvol. 75, pp. 615-622, 1996.
Driscoll et al. “Vitamin A Status Affects the Development of Diabetes and Insulitis in BB Rats”Metabolismvol. 45, No. 2, pp. 248-253, 1996.
Yanagi et al. “Anti-120-kDa α-Fodrin Immune Response with Thl-Cytokine Profile in the NOD Mouse Model of Sjögren's Syndrome”Eur. J. Immunol.vol. 28, pp. 3336-3345, 1998.
Hunter et al. “Retinoic Acid Stimulates Neurite Outgrowth in the Amphibian Spinal Cord”Proc. Natl. Acad. Sci. USAvol. 88, pp. 3666-3670, 1991.
Wuarin et al. “Retinoids Increase Perinatal Spinal Cord Neuronal Survival and Astroglial Differentiation”Int. J. Devl. Neurosciencevol. 8, No. 3, pp. 317-326 (1990).
Haskell et al. “Effect of Retinoic Acid on Nerve Growth Factor Receptors”Cell Tissue Res.vol. 247, pp. 67-73, 1987.
Quinn et al., “Enhanced Neuronal Regeneration by Retinoic Acid of Murine Dorsal Root Ganglia and of Fetal Murine and Human Spinal Cord in Vitro”In Vitro Cell. Dev. Biol.vol. 27A, pp. 55-62, 1991.
Mey, J. “New Therapeutic Target for CNS Injury? The Role of Retinoic Acid Signaling after Nerve Lesions”J. Neurobiol.vol. 66, pp. 757-779, 2006.
Taha et al. “Effect of Retinoic Acid on Tibial Nerve Regeneration After Anastomosis in Rats: Histological and Functional Analyses”Transpl. Proc.vol. 36, pp. 404-408, 2004.
Mozsik et al. “Mechanisms of Action of Retinoids in Gastrointestinal Mucosal Protection in Animals, Human Healthy Subjects and Patients”Life Sci.vol. 69, No. 25-26, pp. 3103-3112, 2001.
Kagechika, H. “Vitamin A no Kino to sono Seigyo Bunshi”Vitaminsvol. 77, No. 9, pp. 501-511, 2003.
Minagawa et al. “4-[3,5-bis(trimethylsilyl)benzamido] Benzoic Acid Inhibits Angiogenesis in Colon Cancer Through Reduced Expression of Vascular Endothelial Growth Factor”Oncol. Res.vol. 14, No. 9, pp. 407-414, 2004.
Shisui et al. “Hikanshiki Retinoid (ACR) wa Rat Daichozengan Byohen oyobi Shuyo Hassei o Yokusei shi Hito Daichogan Saibokabu ni oite apoptosis o Yudo suru,” 64thAnnual Meeting of the Japanese Cancer Association, Sep. 14-16, 2005, vol. 64, pp. 210, Article No. PP1-0479, Aug. 15, 2005.
The Merck Manual, 17thedition (1999), pp. 308-311.
Fukasawa Hiroshi
Ishido Miwako
Kagechika Hiroyuki
Katsumura Naoko
Matsuishi Tetsuro
Greenblum & Bernstein P.L.C.
Kemphys Ltd.
Spivack Phyllis G.
LandOfFree
Method for treatment of adhesion of the intestines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of adhesion of the intestines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of adhesion of the intestines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315008